mRNA provides new therapeutic opportunities for a range of diseases. In vitro transcribed (IVT) mRNA's versatility lies in several key features: simplified cell-free manufacturing, cell cycle independent performance, and insertional-mutagenesis risk-free.
The simple and expedited mRNA manufacturing workflow offers more opportunities for personalized medicines, such as patient-specific cancer vaccines or protein replacement for rare diseases.
GenScript’s solution to mRNA production streamlines your workflow starting from gene synthesis to IVT mRNA production. mRNAs produced at GenScript are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.
Our off-the-shelf mRNA is optimized with 5’ cap and polyA tails that is ready to use for your research needsLearn More
High quality linearized DNA plasmid for better quality and consistency of your mRNA productionLearn More
Institute for Biomedical Sciences at Georgia State University
GenScript mRNA has helped us make a rapid progress in developing novel vaccine projects. GenScript service is faithful and timely provided, saving me lots of time to focus on research. This is why I have been using GenScript services for over 20 years.
|Identification||Appearance||Visual Inspect||Clear and free of foreign particles|
|RNA Length||Capillary Electrophoresis||Target ± 30%|
|RNA Length||Agarose Gel Electrophoresis||Expected size band detected|
|Poly A Length||Enzyme digestion and CE||Target ± 30%|
|RNA Content||UV Absorbance||Target ± 5%|
|PH||pH meter||Target ± 0.5|
|Buffer Specification||Client Spec||N/A|
|Purity||A 260/280 Ratio||UV Spec||1.70 ~ 2.30|
|Capping Efficiency||LC-MS||≥ 90%|
|Size based purity||Capillary Electrophoresis||≥75%|
|Impurity||Total protein residue||Nano Orange Assay||≤ 1%|
|Plasmid DNA Residue||qPCR||≤ 0.1%|
|Bioburden||Sdirect Inoculation||No Growth after
Note: Additional QC and characterizations are offered with an extra charge upon request.
Through this mRNA infographic you will learn about:
IVT mRNA’s key structural features and their function Composition of lipid nanoparticles as a main delivery vehicle IVT mRNA’s therapeutic modalities beyond prophylactic vaccines mRNA candidates progressing through clinical trials